Skip to main content
Clinical Trials/NCT04885049
NCT04885049
Unknown
Not Applicable

A Randomized Controlled Trial Comparing the Efficacy of Anti Secretory and Oral Immunoglobulins Reducing the Episodes of Diarrhea in Children

Shaheed Zulfiqar Ali Bhutto Medical University0 sites60 target enrollmentSeptember 1, 2021

Overview

Phase
Not Applicable
Intervention
Racecadotril
Conditions
Diarrhea
Sponsor
Shaheed Zulfiqar Ali Bhutto Medical University
Enrollment
60
Primary Endpoint
frequency of diarrheal episodes
Last Updated
4 years ago

Overview

Brief Summary

Children 1-12 years presenting/admitted with acute diarrhea will be enrolled in the study after taking informed consent from the parents. Patients will be randomly allocated to two equal groups. Group A (GA) will receive anti secretory 1.5mg/kg/dose, three doses in 24 hours along with oral rehydration, while Group B (GB) will receive a single dose of bovine immunoglobulins. Response to treatment will be assessed by recording the frequency of loose stools after 72 hrs. Data will be collected through a structured proforma.

Detailed Description

It is a randomized clinical trial that will be conducted at Children Hospital PIMS, Islamabad over the period of 6 months. Sample size is calculated using World Health Organization (WHO) calculator, keeping confidence level 95%, level of significance 5%, power of the test 80%,anticipated population proportion 1: 84%, anticipated population proportion 2: 93%, which turn out to be 30.Consecutive non probability sampling technique will be used. Children 1-12 years both male and female visiting/admitted in Children Hospital PIMS with acute diarrhea of less than 15 days duration will be enrolled in the study after taking informed consent from the parents. Children requiring emergency resuscitation, having chronic diarrhea i-e more than 15 days duration, having other comorbid conditions like heart, kidney and liver failure, having metabolic disorder and who are allergic to egg or any of the contents will be excluded from the study. Child's name, age, sex will be recorded by the on duty doctor. Patients will be randomly allocated to two equal groups. Group A (GA) will receive anti secretory 1.5mg/kg/dose three doses per oral in 24 hours along with oral rehydration, while Group B (GB) will receive a single dose of bovine colostrum and egg solids as 7 g of dry powder reconstituted in 30 mL of water and taken orally once daily for 3 days along with oral rehydration. Response to treatment will be assessed by recording the reduction in frequency of diarrheal episodes after administration of drug and duration in which the diarrheal episodes were reduced. Data will be collected through a structured proforma. All data will be analyzed using latest SPSS version. Quantitative variables such as age, time will be presented as means and standard deviations. Qualitative variables such as age groups, sex, recurrence of seizures and efficacy will be measured as frequency and percentages. Effect modifiers like age, gender will be controlled by stratification. Post stratification chi-square test will be applied keeping p value ≤0.05 as significant.

Registry
clinicaltrials.gov
Start Date
September 1, 2021
End Date
February 1, 2022
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr Nighat Haider

Assistant Professor

Shaheed Zulfiqar Ali Bhutto Medical University

Eligibility Criteria

Inclusion Criteria

  • Children 1-12 years both male and female visiting/admitted in Children Hospital PIMS with acute diarrhea of less than 15 days duration

Exclusion Criteria

  • Children requiring emergency resuscitation.
  • Children having diarrhea of more than 15 days duration..
  • Children with other comorbid conditions like heart, kidney and liver failure.
  • Children with fructose intolerance, glucose malabsorption syndrome and saccharase isomaltase deficiency.
  • Children allergic to egg or any of the contents.

Arms & Interventions

Group A

Group A (GA) will receive anti secretory 1.5mg/kg/dose three doses per oral in 24 hours for 3 days along with oral rehydration

Intervention: Racecadotril

Group B

Group B (GB) will receive a single dose of bovine colostrum and egg solids as 7 g of dry powder reconstituted in 30 mL of water and taken orally once daily for 3 days along with oral rehydration

Intervention: DiaResQ Children's Powder for Suspension

Outcomes

Primary Outcomes

frequency of diarrheal episodes

Time Frame: 24 to 72 hours

reduction in frequency of diarrheal episodes after administration of drug

Similar Trials